1. COVID-19 vaccine trials should seek worthwhile efficacy. Issue 10253 (12th September 2020) Authors: Krause, Philip; Fleming, Thomas R; Longini, Ira; Henao-Restrepo, Ana Maria; Peto, Richard; Dean, NE; Halloran, ME; Huang, Y; Fleming, TR; Gilbert, PB; DeGruttola, V; Janes, HE; Krause, PR; Longini, IM; Nason, MC; Peto, R; Smith, PG; Riveros, AX; Gsell, PS; Henao-Restrepo, AM Journal: Lancet Issue: Volume 396:Issue 10253(2020) Page Start: 741 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Maintaining confidentiality of emerging results in COVID-19 vaccine trials is essential. Issue 10263 (21st November 2020) Authors: Krause, Philip R; Fleming, Thomas R; Ellenberg, Susan S; Henao-Restrepo, Ana Maria; Krause, PR; Fleming, T; Alejandria, MM; Bhargava, B; Ellenberg, S; Garcia, PJ; Halloran, E; Henao-Restrepo, AM; Longini, I; Miranda Montoya, MC; Roses, M; Sommerfelt, H Journal: Lancet Issue: Volume 396:Issue 10263(2020) Page Start: 1611 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗